Search
Hundreds of healthy volunteers are needed in Perth to test the effectiveness of a current 'flu vaccine.
An Australian-developed vaccine that's been trialed in Perth has been found to produce a strong immune response against the H5N1 bird flu virus.
Perth children are being asked to volunteer for an important national study to test the effectiveness of an influenza vaccine in children.
Perth researchers are investigating a new combined vaccine to protect against three causes of potentially deadly bacterial meningitis.
Infectious diseases researcher, Dr Asha Bowen, has won the Early Career Scientist of the Year Premier's Science Award for 2017.
Perth researchers are leading an international clinical trial focused on preventing the spread of COVID-19 by testing the effectiveness of the drug interferon in reducing the infectiousness of people who contract the virus.
Coronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.
More children across Australia are being vaccinated against the flu since funding was expanded and access widened under the National Immunisation Program
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.